QHSLab, Inc. (USAQ)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 0 | 1 | 1 | 1 | 2 | 3 | 3 | 3 |
| Operating profit | $m | 0 | 0 | ||||||
| Net profit | $m | -0 | -1 | -1 | -0 | -0 | 0 | 1 | - |
| EPS reported | $ | 0.02 | 0.03 | ||||||
| Operating cashflow per share | $ | 0.02 | 0.00 | ||||||
| Capex per share | $ | 0.00 | 0.00 | ||||||
| FCF per share | $ | 0.02 | 0.00 | ||||||
| Free cash flow | $m | 0 | -0 | ||||||
| Net debt | $m | -1 | -0 | ||||||
| Book value equity | $m | 2 | 2 | ||||||
| Book value per share | $ | 0.08 | 0.07 | ||||||
| Number of shares | m | 19.34 | 23.08 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 30.29 | 15.84 | ||||||
| P/B LTM | x | 4.21 | 4.39 | ||||||
| P/S LTM | x | 2.54 | 2.27 | ||||||
| P/FCF LTM | x | 38.43 | -63.72 | ||||||
| EV/EBITDA LTM | x | 7.93 | 8.67 | ||||||
| EV/Sales LTM | x | 2.31 | 1.24 | ||||||
| Earnings Yield LTM | % | +3.30% | +6.31% | ||||||
| FCF Yield | % | +2.60% | -1.57% | ||||||
| Quality | |||||||||
| ROE | % | +28.15% | +91.63% | ||||||
| ROIC | % | +7.54% | +2.96% | ||||||
| Operating margin | % | +4.88% | +1.76% | ||||||
| Gross margin | % | +67.27% | +66.08% | ||||||
| FCF/Sales | % | +6.62% | +0.99% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +26.26% | +41.52% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | +25.05% | - | ||||||
| Operating Profit Growth | % | -36.21% | -59.84% | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | +0.43% | 0.00% | ||||||
| Dividend Growth | % | -82.27% | -85.14% | ||||||
| Payout Ratio | % | +7.66% | +9.03% | ||||||
| FCF/Debt | x | 8.91 | -1.12 | ||||||
| Net Debt/EBITDA | x | -0.78 | -0.34 | ||||||
| EBIT/Net interest | x | 0.55 | 0.27 | ||||||
| Net debt/market cap | % | +0.29% | +3.53% | ||||||
| Net debt/Equity | x | -0.38 | -0.14 | ||||||
| Gross debt/equity | x | 0.01 | 0.06 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
QHSLab, Inc. is a company operating in the medical technology and Software-as-a-Service (SaaS) sectors. Its core focus is on advancing value-based healthcare, medical informatics, and personalized medicine driven by algorithms. The firm also develops digital therapeutic solutions and on-site technologies intended for remote patient oversight, the management of chronic conditions, and proactive health maintenance. Among its offerings is a proprietary cloud-based SaaS platform, also known as QHSLab (Quality Health Score Lab expert system). This system empowers physicians and healthcare organizations to securely record and store electronic patient data. Additionally, QHSLab, Inc. acts as a distributor, providing primary care physicians with AllergiEnd, a product line encompassing diagnostic tools and allergen immunotherapy treatments. All of its solutions are strategically designed to aid in the prevention, early identification, effective management, and potential reversal of chronic diseases. The company was established in 1983 and is headquartered in West Palm Beach, Florida. It operated under the name USA Equities Corp. until April 2022, when it officially rebranded to QHSLab, Inc. The company also maintains a strategic partnership with Medical License Factory, LLC.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
QHSLab, Inc. is a company operating in the medical technology and Software-as-a-Service (SaaS) sectors. Its core focus is on advancing value-based healthcare, medical informatics, and personalized medicine driven by algorithms. The firm also develops digital therapeutic solutions and on-site technologies intended for remote patient oversight, the management of chronic conditions, and proactive health maintenance. Among its offerings is a proprietary cloud-based SaaS platform, also known as QHSLab (Quality Health Score Lab expert system). This system empowers physicians and healthcare organizations to securely record and store electronic patient data. Additionally, QHSLab, Inc. acts as a distributor, providing primary care physicians with AllergiEnd, a product line encompassing diagnostic tools and allergen immunotherapy treatments. All of its solutions are strategically designed to aid in the prevention, early identification, effective management, and potential reversal of chronic diseases. The company was established in 1983 and is headquartered in West Palm Beach, Florida. It operated under the name USA Equities Corp. until April 2022, when it officially rebranded to QHSLab, Inc. The company also maintains a strategic partnership with Medical License Factory, LLC.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free